<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509392</url>
  </required_header>
  <id_info>
    <org_study_id>CVL-06-03</org_study_id>
    <nct_id>NCT00509392</nct_id>
  </id_info>
  <brief_title>ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.</brief_title>
  <acronym>RECOVERY</acronym>
  <official_title>Radiofrequency Endovenous ClosureFAST vs. Laser Ablation for the Treatment of Great Saphenous Reflux: A Multicenter, Single-Blinded, Randomized Study (RECOVERY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VNUS Medical Technologies, A Covidien Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this post-market study is to compare the post-procedure recovery between two
      types of minimally invasive catheter treatments for venous disease in the Great Saphenous
      Vein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of the post-procedure recovery of radiofrequency (RFA) treatment vs. laser
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>48 Hour</time_frame>
    <description>Pain 0-10 scale (10 most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>1 Week</time_frame>
    <description>Pain 0-10 scale (10 most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Pain 0-10 scale (10 most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>1 Month</time_frame>
    <description>Pain 0-10 scale (10 most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tenderness</measure>
    <time_frame>48 Hour</time_frame>
    <description>Tenderness 0-10 scale (10 most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tenderness</measure>
    <time_frame>1 Week</time_frame>
    <description>Tenderness 0-10 scale (10 most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tenderness</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Tenderness 0-10 scale (10 most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tenderness</measure>
    <time_frame>1 Month</time_frame>
    <description>Tenderness 0-10 scale (10 most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ecchymosis</measure>
    <time_frame>48 Hours post treatment (no baseline)</time_frame>
    <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below treated (tx) segment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ecchymosis</measure>
    <time_frame>1 Week post treatment (no baseline)</time_frame>
    <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ecchymosis</measure>
    <time_frame>2 Weeks post treatment (no baseline)</time_frame>
    <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ecchymosis</measure>
    <time_frame>1 Month post treatment (no baseline)</time_frame>
    <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications</measure>
    <time_frame>1 month</time_frame>
    <description>Sequelae at any follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VCSS</measure>
    <time_frame>48 Hours</time_frame>
    <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VCSS</measure>
    <time_frame>1 Week</time_frame>
    <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VCSS</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VCSS</measure>
    <time_frame>1 Month</time_frame>
    <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CIVIQ QOL</measure>
    <time_frame>48 Hours</time_frame>
    <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CIVIQ QOL</measure>
    <time_frame>1 Week</time_frame>
    <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CIVIQ QOL</measure>
    <time_frame>2 Week</time_frame>
    <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL) (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CIVIQ QOL</measure>
    <time_frame>1 Month</time_frame>
    <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Venous Reflux</condition>
  <arm_group>
    <arm_group_label>Seg. RF Ablation &amp; ClosureFAST catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Seg. RF Ablation &amp; ClosureFAST catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endovenous Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment invention of venous disease with an Endovenous Laser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Seg. RF Ablation &amp; ClosureFAST catheter</intervention_name>
    <description>Seg. RF Ablation &amp; ClosureFAST catheter</description>
    <arm_group_label>Seg. RF Ablation &amp; ClosureFAST catheter</arm_group_label>
    <other_name>VNUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovenous Laser</intervention_name>
    <description>laser catheter</description>
    <arm_group_label>Endovenous Laser</arm_group_label>
    <other_name>Commercially approved laser catheter systems.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must provide written informed consent.

          -  Must be a candidate for either treatment with Radiofrequency Ablation (RFA) or
             endovenous laser.

        Exclusion Criteria:

          -  Subjects who require additional treatments in either leg within 30 days before or
             after the study procedure.

          -  Subjects who are participating in another investigational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lian Cunningham, MD</last_name>
    <role>Study Director</role>
    <affiliation>VNUS Medical Technologies, A Covidien Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health Sciences</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Almeida JI, Kaufman J, Göckeritz O, Chopra P, Evans MT, Hoheim DF, Makhoul RG, Richards T, Wenzel C, Raines JK. Radiofrequency endovenous ClosureFAST versus laser ablation for the treatment of great saphenous reflux: a multicenter, single-blinded, randomized study (RECOVERY study). J Vasc Interv Radiol. 2009 Jun;20(6):752-9. doi: 10.1016/j.jvir.2009.03.008. Epub 2009 Apr 22.</citation>
    <PMID>19395275</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2007</study_first_submitted>
  <study_first_submitted_qc>July 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <results_first_submitted>March 22, 2012</results_first_submitted>
  <results_first_submitted_qc>June 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Varicose veins, venous reflux, GSV disease</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from March - December 2007. Medical offices/clinics and university hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Radiofrequency (RF) Ablation</title>
          <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
        </group>
        <group group_id="P2">
          <title>Endovenous Laser (EVL) Ablation</title>
          <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
        </group>
        <group group_id="P3">
          <title>RF / EVLA</title>
          <description>Bilateral treatment where one limb is treated with RFA and the contralateral limb is treated with EVL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>69 subjects were enrolled and 87 limbs were treated. There were 4 enrolled subjects that had bilateral treatment where one limb was treated with RF and the other limb was treated with EVL. To account for this, 2 subjects were added to the total number of baseline RF participant group and 2 were added to the baseline EVL participant group.</population>
      <group_list>
        <group group_id="B1">
          <title>Radiofrequency (RF) Ablation</title>
          <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
        </group>
        <group group_id="B2">
          <title>Endovenous Laser (EVL) Ablation</title>
          <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="69"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>limbs</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>limbs</units>
          <param>Count of Units</param>
          <units_analyzed>limbs</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" spread="12.8"/>
                    <measurement group_id="B2" value="52.4" spread="15.3"/>
                    <measurement group_id="B3" value="52.37" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>limbs</units>
          <param>Count of Units</param>
          <units_analyzed>limbs</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>limbs</units>
          <param>Number</param>
          <units_analyzed>limbs</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VCSS</title>
          <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="3.1"/>
                    <measurement group_id="B2" value="4.9" spread="2.8"/>
                    <measurement group_id="B3" value="4.8" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CEAP</title>
          <description>Clinical/Etiology/Anatomy/Pathophysiology Score
CEAP Class 2: Clinical classification for individuals with varicose veins</description>
          <units>limbs</units>
          <param>Number</param>
          <units_analyzed>limbs</units_analyzed>
          <class_list>
            <class>
              <title>CEAP Class 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not CEAP Class 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CIVIQ</title>
          <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life (QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions—“pain” (4 items), “physical” (4 items), “psychological” (9 items), and “social” (3 items). A low global (total) score corresponds to greater patient comfort.</description>
          <units>Score on a questionnaire</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="17.2"/>
                    <measurement group_id="B2" value="40" spread="14.5"/>
                    <measurement group_id="B3" value="40.3" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Pain 0-10 scale (10 most severe)</description>
        <time_frame>48 Hour</time_frame>
        <population>Data available at 48 hr follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Pain 0-10 scale (10 most severe)</description>
          <population>Data available at 48 hr follow-up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.9"/>
                    <measurement group_id="O2" value="1.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Pain 0-10 scale (10 most severe)</description>
        <time_frame>1 Week</time_frame>
        <population>Data available at 1-week follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Pain 0-10 scale (10 most severe)</description>
          <population>Data available at 1-week follow-up visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.6"/>
                    <measurement group_id="O2" value="1.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Pain 0-10 scale (10 most severe)</description>
        <time_frame>2 Weeks</time_frame>
        <population>Data available at 2-week follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Pain 0-10 scale (10 most severe)</description>
          <population>Data available at 2-week follow-up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                    <measurement group_id="O2" value="1.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Pain 0-10 scale (10 most severe)</description>
        <time_frame>1 Month</time_frame>
        <population>Data available at 1 month follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Pain 0-10 scale (10 most severe)</description>
          <population>Data available at 1 month follow-up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.8"/>
                    <measurement group_id="O2" value="0.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2962</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tenderness</title>
        <description>Tenderness 0-10 scale (10 most severe)</description>
        <time_frame>48 Hour</time_frame>
        <population>Data available at 48hr visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Tenderness</title>
          <description>Tenderness 0-10 scale (10 most severe)</description>
          <population>Data available at 48hr visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.3"/>
                    <measurement group_id="O2" value="2.0" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tenderness</title>
        <description>Tenderness 0-10 scale (10 most severe)</description>
        <time_frame>1 Week</time_frame>
        <population>Data available at 1-week follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Tenderness</title>
          <description>Tenderness 0-10 scale (10 most severe)</description>
          <population>Data available at 1-week follow-up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.2"/>
                    <measurement group_id="O2" value="1.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tenderness</title>
        <description>Tenderness 0-10 scale (10 most severe)</description>
        <time_frame>2 Weeks</time_frame>
        <population>Data available at 2-week follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Tenderness</title>
          <description>Tenderness 0-10 scale (10 most severe)</description>
          <population>Data available at 2-week follow-up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.7"/>
                    <measurement group_id="O2" value="1.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tenderness</title>
        <description>Tenderness 0-10 scale (10 most severe)</description>
        <time_frame>1 Month</time_frame>
        <population>Data available at 1 month follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Tenderness</title>
          <description>Tenderness 0-10 scale (10 most severe)</description>
          <population>Data available at 1 month follow-up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.0"/>
                    <measurement group_id="O2" value="0.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5761</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ecchymosis</title>
        <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below treated (tx) segment</description>
        <time_frame>48 Hours post treatment (no baseline)</time_frame>
        <population>Data available at 48hrs follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Ecchymosis</title>
          <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below treated (tx) segment</description>
          <population>Data available at 48hrs follow-up visit</population>
          <units>limbs</units>
          <param>Number</param>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ecchymosis</title>
        <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
        <time_frame>1 Week post treatment (no baseline)</time_frame>
        <population>Data available at 1-week follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Ecchymosis</title>
          <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
          <population>Data available at 1-week follow-up visit</population>
          <units>limbs</units>
          <param>Number</param>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ecchymosis</title>
        <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
        <time_frame>2 Weeks post treatment (no baseline)</time_frame>
        <population>Intent to treat/ SP: Data available at 2-week follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Ecchymosis</title>
          <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
          <population>Intent to treat/ SP: Data available at 2-week follow-up visit</population>
          <units>limbs</units>
          <param>Number</param>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ecchymosis</title>
        <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
        <time_frame>1 Month post treatment (no baseline)</time_frame>
        <population>Data available at 1- month follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Ecchymosis</title>
          <description>0-5 scale (5 most severe) 0: None
&lt;25%
25-50%
50-75%
75-100%
Above or below tx segment</description>
          <population>Data available at 1- month follow-up visit</population>
          <units>limbs</units>
          <param>Number</param>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0050</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complications</title>
        <description>Sequelae at any follow-up</description>
        <time_frame>1 month</time_frame>
        <population>Data up to one month follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Complications</title>
          <description>Sequelae at any follow-up</description>
          <population>Data up to one month follow up visit</population>
          <units>limbs</units>
          <param>Count of Units</param>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hyperpigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phlebitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paresthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombus Extention (TE)/Deep Vein Thrombosis (DVT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VCSS</title>
        <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
        <time_frame>48 Hours</time_frame>
        <population>Data at 48 hours for follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>VCSS</title>
          <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
          <population>Data at 48 hours for follow up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.6"/>
                    <measurement group_id="O2" value="6.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VCSS</title>
        <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
        <time_frame>1 Week</time_frame>
        <population>Data at 1-week follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>VCSS</title>
          <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
          <population>Data at 1-week follow up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.5"/>
                    <measurement group_id="O2" value="5.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VCSS</title>
        <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
        <time_frame>2 Weeks</time_frame>
        <population>Data at 2 week follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>VCSS</title>
          <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
          <population>Data at 2 week follow up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.8"/>
                    <measurement group_id="O2" value="5.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VCSS</title>
        <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
        <time_frame>1 Month</time_frame>
        <population>Data at 1- month follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>VCSS</title>
          <description>Venous Clinical Severity Score (0-30 total overall score):
0(minimum)- No evidence of venous disease 30(maximum)- Severe venous disease</description>
          <population>Data at 1- month follow up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="2.2"/>
                    <measurement group_id="O2" value="3.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2825</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CIVIQ QOL</title>
        <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
        <time_frame>48 Hours</time_frame>
        <population>Data at 48 hrs follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CIVIQ QOL</title>
          <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
          <population>Data at 48 hrs follow up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="14.6"/>
                    <measurement group_id="O2" value="-7.1" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0854</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CIVIQ QOL</title>
        <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
        <time_frame>1 Week</time_frame>
        <population>Data at one week follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CIVIQ QOL</title>
          <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
          <population>Data at one week follow up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.1" spread="13.9"/>
                    <measurement group_id="O2" value="-9.4" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0044</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CIVIQ QOL</title>
        <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL) (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
        <time_frame>2 Week</time_frame>
        <population>Data at 2-week follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CIVIQ QOL</title>
          <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL) (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
          <population>Data at 2-week follow up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.9" spread="14.7"/>
                    <measurement group_id="O2" value="-12.4" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0457</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CIVIQ QOL</title>
        <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
        <time_frame>1 Month</time_frame>
        <population>Data at 1 month follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Radiofrequency (RF) Ablation</title>
            <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Laser (EVL) Ablation</title>
            <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CIVIQ QOL</title>
          <description>Chronic Venous Insufficiency Questionnaire(CIVIQ) for Quality of Life(QOL). (Min 20- Max 100).
Global index and an outline of 4 quality-of-life dimensions: &quot;pain&quot; (4 items), &quot;physical&quot; (4 items), &quot;psychological&quot; (9 items), and &quot;social&quot; (3 items). A low global (total) score corresponds to greater patient comfort.
Change from Baseline</description>
          <population>Data at 1 month follow-up visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" spread="15.4"/>
                    <measurement group_id="O2" value="-17.5" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9463</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Month</time_frame>
      <desc>Number of subjects at risk = Number of subjects with adverse event information</desc>
      <group_list>
        <group group_id="E1">
          <title>Radiofrequency (RF) Ablation</title>
          <description>Radiofrequency (RF) thermal ablation using the ClosureFAST (CLF) RF Catheter (VNUS Medical Technologies, San Jose, CA)</description>
        </group>
        <group group_id="E2">
          <title>Endovenous Laser (EVL) Ablation</title>
          <description>Endovenous Laser (EVL) ablation with a 980-nm laser (Biolitec, East Longmeadow, MA)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombus extension (TE) into Common Femoral Vein (CFV)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The data/info related to Study are legal property of VNUS &amp; can be used by PI for publication, communication or scientific presentation only after duly informing VNUS of proposed dissemination, providing to VNUS for review/comment a copy of said proposed publication, communication or scientific presentation &amp; allowing at least 30 days from the time of receipt by VNUS for VNUS to provide comment on said proposed publication, communication or scientific presentation prior to said dissemination.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eppie Chang, MS; Director Clinical Research</name_or_title>
      <organization>VNUS Medical Technologies / Covidien (sponsor)</organization>
      <phone>408-360-7200</phone>
      <email>eppie.chang@covidien.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

